New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 28, 2013
04:55 EDTATOS, ATOS, RHHBY, RHHBY, SQNM, SQNM, GHDX, GHDX, SAP, SAP, AET, AET, IBM, IBM, UNH, UNHPMWC, Inc to host a conference
Personalized Medicine World Conference is being held in Mountain View, California on January 28-29.
News For ATOS;RHHBY;SQNM;GHDX;SAP;AET;IBM;UNH From The Last 14 Days
Check below for free stories on ATOS;RHHBY;SQNM;GHDX;SAP;AET;IBM;UNH the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
August 24, 2014
21:54 EDTSQNMPiper Jaffray to hold a bus tour
Subscribe for More Information
21:53 EDTUNHNational Association of Chain Drug Stores to hold an expo
2014 NACDS Total Store Expo to be held in Boston on August 23-25.
20:27 EDTRHHBYRoche drops pursuit for remainder of Japan's Chugai, Bloomberg says
Subscribe for More Information
13:41 EDTRHHBYRoche to acquire InterMune for $74.00 per share
Roche (RHHBY) and InterMune (ITMN) announced they have entered into a definitive merger agreement for Roche to fully acquire InterMune at a price of $74.00 per share in an all-cash transaction. This corresponds to a total transaction value of $8.3B on a fully diluted basis. This offer represents a premium of 38% to InterMune's closing price on August 22 and a premium of 63% to InterMune's unaffected closing price on August 12. The merger agreement has been approved by the boards of InterMune and Roche. Under the terms of the merger agreement, Roche will commence a tender offer no later than August 29 to acquire all outstanding shares of InterMune common stock, and InterMune will file a recommendation statement containing the unanimous recommendation of the InterMune board that InterMune's shareholders tender their shares to Roche. The transaction is expected to be neutral to core earnings per share in 2015 and accretive from 2016 onwards. The acquisition of InterMune, a Brisbane, California based biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and fibrotic diseases, will allow Roche to broaden and strengthen its respiratory portfolio globally. Roche plans a smooth transition of InterMune employees and operations into the Roche organization, ensuring readiness for an expected launch of pirfenidone in the US in 2014. The closing of the transaction is expected to take place in 2014.
August 22, 2014
07:08 EDTIBMIBM says China bank server business still alive, China Daily reports
Subscribe for More Information
August 21, 2014
11:44 EDTIBMHP hits 52-week high after solid revenue growth, positive analyst commentary
Subscribe for More Information
09:03 EDTIBMIBM cloud technology selected by Wespac
Subscribe for More Information
09:02 EDTIBMIBM's private cloud resilence services selected by Ujjivan Financial
Subscribe for More Information
09:01 EDTIBMIBM partners with Veda
Subscribe for More Information
August 20, 2014
08:10 EDTATOSAtossa Genetics submits additional information to the FDA in support of ForeCYTE
Atossa Genetics announced that it has submitted additional information to the FDA in response to the FDA's February 21 request. The information was provided in support of Atossa's 510(k) submission for the ForeCYTE Breast Aspirator. The response includes, among other things: Data from an IRB-approved, prospective, single-arm, multi-laboratory, non-randomized, non-masked clinical trial in adult women using the ForeCYTE Breast Aspirator for the collection, fixation, transport, and processing of NAF specimens for laboratory cytological testing at multiple, independent CLIA-registered laboratories. A study of the concordance of positive and negative control Reference Panel Specimens with a blinded cytological interpretation when the specimens were processed and read at multiple, independent laboratories. Study data to establish shelf life information and document shipping stability under adverse conditions of the ForeCYTE Breast Aspirator. Based on the information provided to the FDA, Atossa expects that the FDA will finalize their review process, which may include requests for additional information, and will either clear Atossa's 510(k) submission or provide a "not substantially equivalent" decision on Atossa's 510(k) submission.
August 19, 2014
11:32 EDTSQNMLabCorp prenatal test a negative for Sequenom, says Maxim
Maxim views LabCorp's (LH) announcement today that it will begin offering the informaSeq prenatal test as a long-term negative for Sequenom (SQNM) due to increased competition. The news is also negative for Illumina (ILMN) and PerkinElmer (PKI), who both offer Non-Invasive Prenatal Tests, Maxim adds. The firm recommends buying shares of LabCorp and keeps a Buy rating on the name with a $130 price target.
11:05 EDTIBMImperva seen as takeover candidate under new CEO
Subscribe for More Information
08:42 EDTIBMImperva new CEO has history of selling companies, says Sterne Agee
After Imperva (IMPV) appointed Anthony Bettencourt as its new CEO, Sterne Agee says that he has a history of selling companies. The firm believes that Imperva "would likely be an acquisition candidate" for a number of large tech companies such as Cisco (CSC), Juniper (JNPR), HP (HPQ), IBM (IBM), Check Point (CHKP), or F5 (FFIV). Sterne Agee believes that Imperva could be acquired for as much as $45 per share, and it keeps a Buy rating on the stock.
05:29 EDTSAPSAP invests $500M in Africa
SAP announced a seven-year plan to up-skill local African talent and drive sustainable innovation and growth in Africa. With more than 1,300 customers across the continent, SAP is already enabling African businesses and governments of all sizes to grow, scale and globalize, as well as make the transition to a networked, technology-driven innovative economy. As part of this commitment, SAP Africa is now taking responsibility for SAP operations across 51 African countries, including Morocco, Algeria and Tunisia and Mauritania.With the vision of helping make Africa run better and improve the lives of Africans, SAP plans to invest up to $500M through 2020 as it continues to build on the region's impressive double-digit growth rate momentum. The goal is to establish the African region as one of the company's top-five growth markets globally. Much of the direct investment will be outside South Africa, where SAP already has a solid footprint.
August 18, 2014
09:06 EDTSAPSGI opens new German subsidiary
Subscribe for More Information
August 17, 2014
13:40 EDTRHHBYChugai makes statement denying media reports on Roche deal
Subscribe for More Information
August 15, 2014
16:10 EDTIBMIBM issues statement on U.S. regulatory approval of x86 server sale to Lenovo
Subscribe for More Information
11:28 EDTRHHBYRoche in talks on $10B deal to buy remainder of Chugai, Bloomberg reports
Roche is in talks to purchase the 38% stake of Chugai Pharmaceutical that it doesn't already own, according to Bloomberg, citing people familiar with the matter. The potential deal is valued at approximately $10B. Though no financial decision has been made, the deal may be announced as early as next week, the sources added. Reference Link
11:02 EDTRHHBYRoche in talk on $10B deal to buy remainder of Chugai, Bloomberg says
Subscribe for More Information
06:12 EDTRHHBYGilead announced favorable ruling in arbitration against Roche
Gilead (GILD) announced that an arbitration panel determined that Roche (RHHBY) failed to establish any of their claims and ruled in favor of Gilead. As a result, Roche is not entitled to any damages or other relief. In March 2013, Roche initiated an arbitration against Gilead and Pharmasset, predecessor to Gilead Pharmasset, regarding a 2004 collaboration agreement between Roche and Pharmasset. In the arbitration demand, Roche asserted that it had an exclusive license to sofosbuvir pursuant to the collaboration agreement because sofosbuvir, a prodrug of a uridine monophosphate analog, is allegedly a prodrug of PSI-6130, a cytidine analog. Roche further claimed that, because it had exclusive rights to sofosbuvir, it also had an exclusive license to a patent covering sofosbuvir, and that we infringed that patent by selling and offering for sale products containing sofosbuvir.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use